These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32259468)

  • 1. Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer.
    Ranasinghe W; Reichard CA; Nyame YA; Sundi D; Tosoian JJ; Wilkins L; Alam R; Achim MF; Wang X; Stephenson AJ; Klein EA; Ross AE; Allaf ME; Davis JW; Chapin BF
    J Urol; 2020 Oct; 204(4):748-753. PubMed ID: 32259468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy.
    Liu H; Tang K; Xia D; Peng E; Wang L; Chen Z
    Pathol Res Pract; 2020 Nov; 216(11):153235. PubMed ID: 33035728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downgrading of biopsy based Gleason score in prostatectomy specimens.
    Treurniet KM; Trudel D; Sykes J; Evans AJ; Finelli A; Van der Kwast TH
    J Clin Pathol; 2014 Apr; 67(4):313-8. PubMed ID: 24403214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nomogram Predicting Downgrading in National Comprehensive Cancer Network High-risk Prostate Cancer Patients Treated with Radical Prostatectomy.
    Wenzel M; Würnschimmel C; Chierigo F; Flammia RS; Tian Z; Shariat SF; Gallucci M; Terrone C; Saad F; Tilki D; Graefen M; Becker A; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
    Eur Urol Focus; 2022 Sep; 8(5):1133-1140. PubMed ID: 34334344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with downgrading in patients with high grade prostate cancer.
    Whitson JM; Porten SP; Cowan JE; Simko JP; Cooperberg MR; Carroll PR
    Urol Oncol; 2013 May; 31(4):442-7. PubMed ID: 21478037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance.
    Su ZT; Patel HD; Epstein JI; Pavlovich CP; Allaf ME
    Cancer; 2020 Apr; 126(8):1632-1639. PubMed ID: 32031685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of PSMA PET/CT in predicting downgrading in patients with Gleason score 4+4 prostate cancer in prostate biopsy.
    Aykanat IC; Kordan Y; Seymen H; Koseoglu E; Ozkan A; Esen B; Tarim K; Kulac I; Falay O; Gurses B; Baydar DE; Canda AE; Balbay MD; Demirkol MO; Esen T
    World J Urol; 2024 May; 42(1):341. PubMed ID: 38771329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of "regression to the mean" using routine clinical features with correlating biochemical relapse rates.
    Altok M; Troncoso P; Achim MF; Matin SF; Gonzalez GN; Davis JW
    Asian J Androl; 2019; 21(6):598-604. PubMed ID: 31115364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should all prostate needle biopsy Gleason score 4 + 4 = 8 prostate cancers be high risk? Implications for shared decision-making and patient counselling.
    Ginsburg K; Cole AI; Silverman ME; Livingstone J; Smith DW; Heilbrun LK; Shi D; Mehra R; Sakr WA; Morgan TM; Cher ML
    Urol Oncol; 2020 Mar; 38(3):78.e1-78.e6. PubMed ID: 31791703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology.
    Sorce G; Stabile A; Pellegrino F; Mazzone E; Mattei A; Afferi L; Serni S; Minervini A; Roumiguiè M; Malavaud B; Valerio M; Rakauskas A; Marra G; Gontero P; Porpiglia F; Guo H; Zhuang J; Gandaglia G; Montorsi F; Briganti A
    World J Urol; 2024 Apr; 42(1):248. PubMed ID: 38647689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.
    Epstein JI; Feng Z; Trock BJ; Pierorazio PM
    Eur Urol; 2012 May; 61(5):1019-24. PubMed ID: 22336380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer.
    Gondo T; Poon BY; Matsumoto K; Bernstein M; Sjoberg DD; Eastham JA
    BJU Int; 2015 Jan; 115(1):81-6. PubMed ID: 24725760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proportion of cores with the highest Gleason grade group among positive cores on prostate biopsy: does this affect the probability of upgrading or downgrading?
    Yoo S; Suh J; Park J; Cho MC; Son H; Jeong H
    Scand J Urol; 2019 Dec; 53(6):372-377. PubMed ID: 31674877
    [No Abstract]   [Full Text] [Related]  

  • 15. Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy.
    Qi R; Foo WC; Ferrandino MN; Davis LG; Sekar S; Longo TA; Jibara G; Han T; Gokhan I; Moul JW
    Can J Urol; 2017 Oct; 24(5):8982-8989. PubMed ID: 28971784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Most Gleason 8 Biopsies are Downgraded at Prostatectomy-Does 4 + 4 = 7?
    Gansler T; Fedewa S; Qi R; Lin CC; Jemal A; Moul JW
    J Urol; 2018 Mar; 199(3):706-712. PubMed ID: 29032296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate magnetic resonance imaging-targeted biopsy global grade correlates better than highest grade with prostatectomy grade.
    Ren J; Melamed J; Taneja SS; Wysock JS; Huang WC; Lepor H; Deng FM
    Prostate; 2023 Mar; 83(4):323-330. PubMed ID: 36461793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading.
    Donohue JF; Bianco FJ; Kuroiwa K; Vickers AJ; Wheeler TM; Scardino PT; Reuter VA; Eastham JA
    J Urol; 2006 Sep; 176(3):991-5. PubMed ID: 16890678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative upgrading of prostate cancer in men ≥75 years: a propensity score-matched analysis.
    Herlemann A; Buchner A; Kretschmer A; Apfelbeck M; Stief CG; Gratzke C; Tritschler S
    World J Urol; 2017 Oct; 35(10):1517-1524. PubMed ID: 28493044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications.
    Freedland SJ; Kane CJ; Amling CL; Aronson WJ; Terris MK; Presti JC;
    Urology; 2007 Mar; 69(3):495-9. PubMed ID: 17382152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.